Medication info

Olmesartan Medoxomil and Rosuvastatin Tablets 20/5 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletRosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
White Biotechnology Co., Ltd.
Appearance
White or light yellow round film-coated tablets
Packaging
30 tablets (10 tablets/Alu-Alu) × 3
Approval status
Expired

MFDS item code 202003970 · Approved 2020.05.28

This product's status changed to Expired on 2025.05.28. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, inhibition of atherosclerosis progression and prevention of cardiovascular disease
Who takes it
Adults · Children
Adult dose
This medicine is for adults only. The dose should be individualized for each patient based on the effects and tolerability of each of the active ingredients, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, regardless of meals. If blood pressure is not adequately controlled at this dose, increase to 20mg once daily. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 40mg daily. The blood-pressure-lowering effect appears within 2 weeks after starting treatment and reaches its maximum at about 8 weeks. If blood pressure is not controlled with this medicine alone, it may be given in combination with a thiazide diuretic, such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day (e.g., in the morning), if possible. For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended that treatment be initiated at a low dose with close monitoring of their condition. 2. Elderly patients No dose adjustment is needed when this medicine is administered to patients aged 65 years or older. Although no overall differences in efficacy or safety have been observed between elderly and younger patients, a more sensitive response in some elderly patients cannot be ruled out. 3. Patients with renal impairment The maximum dose for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dose adjustment is needed for patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10mg once daily, and it may be increased to a maximum of 20mg daily. Since there is no experience with use in patients with severe hepatic impairment, administration of this medicine is not recommended. ◆ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; it may be increased to a maximum of 20 milligrams daily. 2. Elderly patients No dose adjustment is needed. 3. Patients with renal impairment No dose adjustment is needed for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. Patients taking olmesartan medoxomil and rosuvastatin concomitantly may switch to this medicine (a combination product with the same strengths of each active ingredient) for convenience.
Child dose
Safety and efficacy have not been established in children under 18 years of age.

Ingredients

Manufacturer
White Biotechnology Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, inhibition of atherosclerosis progression and prevention of cardiovascular disease

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary artery disease.
View approved original text

This medication is used for patients who need to take both olmesartan medoxomil and rosuvastatin simultaneously. Olmesartan medoxomil helps to treat essential hypertension. Rosuvastatin is used as an adjunct therapy when controlling conditions such as hypercholesterolemia and mixed dyslipidemia through diet and exercise is difficult. It is also effective in reducing the risks of stroke, myocardial infarction, and vascular revascularization in patients at high risk for cardiovascular diseases. This medication is used to manage hypertension and hyperlipidemia together to improve cardiovascular health.

How to take

Adult dose

This medicine is for adults only. The dose should be individualized for each patient based on the effects and tolerability of each of the active ingredients, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, regardless of meals. If blood pressure is not adequately controlled at this dose, increase to 20mg once daily. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 40mg daily. The blood-pressure-lowering effect appears within 2 weeks after starting treatment and reaches its maximum at about 8 weeks. If blood pressure is not controlled with this medicine alone, it may be given in combination with a thiazide diuretic, such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day (e.g., in the morning), if possible. For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended that treatment be initiated at a low dose with close monitoring of their condition. 2. Elderly patients No dose adjustment is needed when this medicine is administered to patients aged 65 years or older. Although no overall differences in efficacy or safety have been observed between elderly and younger patients, a more sensitive response in some elderly patients cannot be ruled out. 3. Patients with renal impairment The maximum dose for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dose adjustment is needed for patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10mg once daily, and it may be increased to a maximum of 20mg daily. Since there is no experience with use in patients with severe hepatic impairment, administration of this medicine is not recommended. ◆ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; it may be increased to a maximum of 20 milligrams daily. 2. Elderly patients No dose adjustment is needed. 3. Patients with renal impairment No dose adjustment is needed for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. Patients taking olmesartan medoxomil and rosuvastatin concomitantly may switch to this medicine (a combination product with the same strengths of each active ingredient) for convenience.

Child dose

Safety and efficacy have not been established in children under 18 years of age.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. It should not be used by individuals allergic to its ingredients, pregnant or breastfeeding women, and fertile women not using appropriate contraception. Patients with very poor kidney function or undergoing dialysis, severe liver impairment, and those with certain liver or muscle diseases should not take this medication. Patients with very low blood pressure or low sodium levels may experience hypotensive symptoms when starting this medication, so caution is required, and such symptoms should be reported to a healthcare professional immediately. This medication can affect kidney function; therefore, patients with poor kidney function should periodically check their kidney status through blood tests. Due to the risk of hyperkalemia, it is important to regularly check blood potassium levels. If symptoms of muscle pain or weakness occur, notify a healthcare professional immediately and undergo necessary testing; in severe cases, the medication should be discontinued. This medication may also affect liver function, so liver function tests should be performed regularly, and if signs of liver damage occur, it should be discontinued immediately. Dizziness might occur, so be cautious when engaging in dangerous activities such as high-elevation work or driving. This medication may interact with other drugs, so inform your healthcare professional of any other medications you are taking, especially when taking potassium-sparing diuretics or certain antibiotics, antifungals, and immunosuppressants. Do not take this medication if pregnant or breastfeeding, and women planning pregnancy should use appropriate contraceptive methods. For children and adolescents under 18 years old, it is advisable not to use it as safety and efficacy have not been established. In elderly patients, drug concentration in the body may increase, requiring dosage adjustment and caution. Overdose can cause symptoms such as hypotension or palpitations; in this case, visit a medical institution immediately for appropriate treatment. This medication should be stored out of reach of children and should not be transferred to other containers.

Side effects

Increased ALT, increased AST, elevated blood creatinine, decreased creatinine clearance, headache, dizziness, sensory impairment, neuropathy, drowsiness, gastroesophageal reflux disease, constipation, dental caries, dyspepsia, gastric ulcer, gastritis, gastroenteritis, musculoskeletal stiffness, atrial fibrillation, hypoglycemia, chest pain, tooth extraction, chest discomfort, peripheral edema, vertigo, abdominal pain, nausea, palpitations, hypercholesterolemia, hyperlipidemia, hyperuricemia, arthralgia, arthritis, myalgia, rash, facial edema, asthenia, angioedema, anaphylaxis, vomiting, chronic malabsorption syndrome, rhabdomyolysis, hyperkalemia, acute renal failure, hair loss, pruritus, urticaria, autoimmune hepatitis, dizziness (including positional vertigo), palpitations, increased blood pressure, lumbago, diarrhea, cough, epistaxis, upper respiratory infection, asthma, hypersensitivity reactions including angioedema, diabetes, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, memory loss, peripheral neuropathy, dyspnea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is recommended to maintain storage temperatures between 1 degree and 30 degrees Celsius. This will help safely preserve the medication's efficacy.

Appearance and packaging

Appearance

White or light yellow round film-coated tablets

Package unit

30 tablets (10 tablets/Alu-Alu) × 3

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.